FDA Approves New Type of Drug for Migraine Treatment

The U.S. Food and Drug Administration approved a new pill for treatment of migraine headaches. The FDA granted approval of Reyvow, or lasmiditan, to Eli Lilly and Co. The company said Reyvow is the first drug in a new class of acute treatment for migraine. Reyvow is thought to work by binding to a serotonin receptor, 5-HT(1F). “Considering up to 40% of people with migraine do not get adequate responses from their initial acute treatment prescription, having a new and novel option like Reyvow is an important development,” Dr. Jan Brandes, of Vanderbilt University, said in an Eli L...